Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
Open Access
- 6 December 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 9, 3026
- https://doi.org/10.3389/fmicb.2018.03026
Abstract
The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza A and B virus infections in February 2018 in Japan. Because of the need to monitor influenza viruses for reduced susceptibility to this drug, we used two cell-based screening systems – a conventional plaque reduction assay and a focus reduction assay – to evaluate the susceptibility of influenza viruses to baloxavir. First, we generated a reference virus possessing an I38T substitution in the polymerase acidic subunit (PA), which is known to be associated with reduced susceptibility to baloxavir, and demonstrated the validity of our systems using this reference virus. We then determined the susceptibility of a panel of neuraminidase (NA) inhibitor-resistant viruses and their sensitive counterparts to baloxavir. No significant differences in baloxavir susceptibilities were found between the NA inhibitor-resistant and -sensitive viruses. We also examined seasonal influenza viruses isolated during the 2017–2018 influenza season in Japan and found that no currently circulating A(H1N1)pdm09, A(H3N2), or B viruses had significantly reduced susceptibility to baloxavir and none of the viruses possessed an amino acid substitution at PA residue 38. Use of a combination of methods to analyze antiviral susceptibility and detect amino acid substitutions is valuable for monitoring the emergence of baloxavir-resistant viruses.This publication has 21 references indexed in Scilit:
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and AdolescentsThe New England Journal of Medicine, 2018
- Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease InhibitorsmBio, 2018
- Influenza antivirals currently in late‐phase clinical trialInfluenza and Other Respiratory Viruses, 2017
- Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza VirusesPLoS Pathogens, 2014
- Impact of Potential Permissive Neuraminidase Mutations on Viral Fitness of the H275Y Oseltamivir-Resistant Influenza A(H1N1)pdm09 VirusIn Vitro, in Mice and in FerretsJournal of Virology, 2014
- Enhanced Mammalian Transmissibility of Seasonal Influenza A/H1N1 Viruses Encoding an Oseltamivir-Resistant NeuraminidaseJournal of Virology, 2012
- Role of Permissive Neuraminidase Mutations in Influenza A/Brisbane/59/2007-like (H1N1) VirusesPLoS Pathogens, 2011
- Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir ResistanceScience, 2010
- New low-viscosity overlay medium for viral plaque assaysVirology Journal, 2006
- Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy StudiesAntimicrobial Agents and Chemotherapy, 2000